Seeking Alpha

PTC Therapeutics more than doubles as Ataluren gets positive opinion

  • PTC Therapeutics (PTCT) +119.2% premarket after the Committee for Medicinal Products for Human Use of the European Medicines Agency issues a positive opinion on PTCT's application for a conditional marketing authorization of its Ataluren muscular dystrophy treatment.
  • The news is a major upside surprise: Credit Suisse says a potential early EU approval for Ataluren has not been priced in to shares.
  • Others involved in Duchenne muscular dystrophy treatments also trade higher premarket: RNA +16%, SRPT +3%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: